Streetbeat News

Products Services

GOVX

GeoVax Labs, Inc. (NASDAQ:GOVX) has signed a commercial license agreement with ProBioGen for its AGE1.CR.pIX® suspension cell line. This will enhance GeoVax's manufacturing capabilities for its entire Modified Vaccinia Ankara (MVA) based vaccine portfolio. The AGE1.CR.pIX cell line enables high-yield and scalable production, leading to cost-effectiveness and increased productivity for vaccine developers. Financial terms of the agreement were not disclosed.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2023 | 1:23 pm

SNX

Spin.AI and TD SYNNEX have partnered to provide SaaS security solutions to resellers and customers. The all-in-one SaaS security platform, SpinOne, will be available to TD SYNNEX partners and customers worldwide, aiming to reduce security and compliance risks associated with data theft, leak, and loss.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2023 | 1:23 pm

TBLA

Taboola (NASDAQ:TBLA) has announced a multi-year deal with Advance Local to increase user engagement and monetization opportunities. Advance Local will use Taboola's suite of products to grow its audience, optimize user engagement, and drive revenue. The deal includes the use of Taboola Feed, mid-article and right rail placements, and testing of additional offerings such as Header Bidding and Taboola Turnkey Commerce.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2023 | 1:22 pm

LXRX

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) announced several upcoming data presentations related to heart failure, type 1 diabetes, and diabetic peripheral neuropathic pain at the 59th Annual Meeting of EASD. The presentations will include results from studies on INPEFA® (sotagliflozin), recently approved by FDA for heart failure treatment, and LX9211, an investigational, non-opioid treatment for diabetic peripheral neuropathic pain. LX9211 has received Fast Track designation from the FDA and is expected to advance into late-stage development before the end of 2023.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2023 | 1:22 pm

NRXS

NeurAxis (NYSE:NRXS) announced the results of a comparative study of adolescent patients with functional abdominal pain disorders (FAPD) treated with IB-Stim™ therapy or standard of care medications. The study concluded that IB-Stim™ may be a good non-pharmacologic alternative for FAPD. The study showed that IB-Stim™ therapy showed improvements in abdominal pain and functional disability compared to baseline, while amitriptyline showed improvements in abdominal pain. IB-Stim™ was more effective than cyproheptadine in improving abdominal pain and did not differ from amitriptyline.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2023 | 1:21 pm

LUMO

Lumos Pharma, Inc. (NASDAQ:LUMO) presented new data and analysis from its OraGrowtH212 Trial at the 2023 ESPE Annual Meeting. The analysis shows a 60% increase in GH secretion and a 62% increase in annualized height velocity compared to baseline. The data supports the mechanism of action for LUM-201, Lumos' oral therapeutic candidate for moderate Pediatric Growth Hormone Deficiency (PGHD), currently in Phase 2 clinical trials. The company expects topline data from these trials in the fourth quarter.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2023 | 1:20 pm

SNPX

Synaptogenix, Inc. (NASDAQ:SNPX) has announced the publication of a peer-reviewed paper detailing the results of a Phase 2 clinical trial for Bryostatin-1, a drug developed for the treatment of Alzheimer's disease. The trial demonstrated statistically significant benefits of Bryostatin-1 in advanced Alzheimer's patients, with no significant cognitive decline observed over a 10-month period. The trial was sponsored by the National Institute on Aging (NIA) and the National Cancer Institute (NCI), both part of the NIH.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2023 | 1:17 pm

AMZN

DRCT

Direct Digital Holdings, Inc. (NASDAQ:DRCT) has announced a collaboration with Amazon Publisher Services. The collaboration will see Direct Digital's Supply-Side Platform, Colossus SSP, integrate with Amazon's Transparent Ad Marketplace (TAM). This integration will provide Colossus SSP's publishers with access to TAM's server-side header bidding solutions, offering a direct auction approach. The collaboration is expected to provide direct, premium, transparent, and scalable advertising opportunities.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2023 | 1:15 pm

VUZI

Vuzix Corporation (NASDAQ:VUZI), a leading supplier of Smart Glasses and Augmented Reality (AR) technology, has announced the commencement of waveguide production at its new state-of-the-art manufacturing facility. The facility, which is located adjacent to the company's headquarters, will significantly increase unit capacity and lower manufacturing costs. The waveguides produced will be used in products based on the company's Ultralite OEM Platform.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2023 | 1:14 pm

CTLT

Melt Pharmaceuticals has entered into an exclusive development and license agreement with Catalent for its Zydis fast-dissolve technology. The technology will be used in MELT-300, a needle- and opioid-free formulation for procedural sedation during cataract surgery. MELT-300, which combines fixed doses of midazolam and ketamine, is administered sublingually and uses Zydis ODT technology to rapidly dissolve the tablet for absorption. Melt Pharmaceuticals is currently in discussions with the FDA on the Phase 3 program, which is expected to begin in early 2024.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2023 | 1:13 pm